Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition — A Descriptive Observational Retrospective Multicenter Analysis

INTRODUCTION: Immune checkpoint inhibitors (ICI) are increasingly being used to treat numerous cancer types. Together with improved recognition of toxicities, this has led to more frequent identification of rare immune-related adverse events (irAE), for which specific treatment strategies are needed...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaremba, Anne, Kramer, Rafaela, De Temple, Viola, Bertram, Stefanie, Salzmann, Martin, Gesierich, Anja, Reinhardt, Lydia, Baroudjian, Barouyr, Sachse, Michael M., Mechtersheimer, Gunhild, Johnson, Douglas B., Weppler, Alison M., Spain, Lavinia, Loquai, Carmen, Dudda, Milena, Pföhler, Claudia, Hepner, Adriana, Long, Georgina V., Menzies, Alexander M., Carlino, Matteo S., Lebbé, Céleste, Enokida, Tomohiro, Tahara, Makoto, Bröckelmann, Paul J., Eigentler, Thomas, Kähler, Katharina C., Gutzmer, Ralf, Berking, Carola, Ugurel, Selma, Stadtler, Nadine, Sucker, Antje, Becker, Jürgen C., Livingstone, Elisabeth, Meier, Friedegund, Hassel, Jessica C., Schadendorf, Dirk, Hanoun, Maher, Heinzerling, Lucie, Zimmer, Lisa
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567012/
https://www.ncbi.nlm.nih.gov/pubmed/34746007
http://dx.doi.org/10.3389/fonc.2021.765608

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8567012/
https://www.ncbi.nlm.nih.gov/pubmed/34746007
http://dx.doi.org/10.3389/fonc.2021.765608

Ejemplares similares